CHB


China Biotech Innovation ETF

Fund Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

Fund Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Why CHB?

High Growth Potential

CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.

Targeted Exposure

CHB delivers targeted exposure to an emerging theme and industry.

ETF Efficiency

In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.

Fund Details As of 03/05/21

Key Facts

Ticker CHB
Inception Date 09/22/20
CUSIP 37954Y251
ISIN US37954Y2515
Bloomberg Index Ticker SOLCHB
Primary Exchange Nasdaq
Number of Holdings 31

Stats & Fees

Net Assets $4,817,518
Net Asset Value (NAV) $16.06
Shares Outstanding 300,000
Total Expense Ratio 0.65%

Distributions

30-Day SEC Yield N/A
Distribution Frequency Semi-Annually

Fund Prices As of 03/05/21

NAV $16.06 Daily Change -$0.05 -0.32%
Market Price $16.07 Daily Change -$0.03 -0.16%
30-Day Median Bid-Ask Spread 0.50%

Performance History

As of recent
(12/31/20)
Fund NAV Market Price Index
Year-to-Date -- -- --
1 Month 9.74% 9.73% 9.80%
3 Months 6.59% 5.89% 6.79%
Since Inception 8.22% 8.42% 8.44%
Year-to-Date 3.49% 4.46% 3.59%
1 Month -2.54% -1.67% -2.47%
3 Months 13.58% 14.62% 13.75%
Since Inception 11.99% 13.25% 12.33%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Fund Characteristics

Return on Equity 7.50%
Weighted Avg. Market Cap 6,615 M
2020 2021
Price-to-earnings 143.48 78.36
Price-to-book value 6.01 5.71

Source: AltaVista Research, LLC

Top Holdings As of 03/05/21

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
9.24 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 11.53 38,600 444,955.34
8.87 000661 C2 CHANGCHUN HIGH-A BD5CDB3 64.75 6,600 427,373.23
7.77 BGNE BEIGENE LTD-ADR BYYWPW6 301.28 1,242 374,189.76
7.13 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 6.67 51,500 343,607.17
7.05 ZLAB ZAI LAB LTD-ADR BD9GVY0 137.25 2,474 339,556.50
6.58 300601 C2 SHENZHEN KANGT-A BFY8HT2 21.90 14,471 316,884.67
4.93 300357 C2 ZHEJIANG WOLWO-A BFY8GY0 10.16 23,400 237,703.92
4.50 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 1.07 203,100 216,593.96
4.26 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 20.04 10,238 205,127.45
3.55 002007 C2 HUALAN BIOLOGI-A BD5CL19 6.36 26,900 171,018.28
3.55 300725 C2 PHARMABLOCK SC-A BFY8HC5 23.56 7,255 170,953.96
3.36 603345 C1 FU JIAN ANJOY-A BMXWM11 31.69 5,100 161,609.25
3.29 600201 C1 JINYU BIO-TECH-A BP3RBF4 3.31 47,900 158,545.05
3.19 300009 C2 ANHUI ANKE BIO-A BD5C829 2.23 68,900 153,761.62
2.63 002030 C2 DA AN GENE CO -A BD5CKW3 4.92 25,700 126,493.60
2.60 002422 C2 SICHUAN KELUN-A BD5CL08 3.06 40,900 125,213.04
2.48 600161 C1 BEIJING TIAN-A BP3R9J4 5.36 22,257 119,242.46
2.44 CBPO CHINA BIOLOGIC P BF0G7L2 117.76 1,000 117,760.00
2.00 002252 C2 SHANGHAI RAAS -A BD5CPJ5 1.20 80,400 96,187.00
1.90 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 1.74 52,550 91,507.25
1.54 603127 C1 JOINN LABORATO-A BK94819 19.03 3,900 74,197.98
1.46 1530 HK 3SBIO INC BY9D3L9 0.96 72,900 70,232.03
0.95 000710 C2 BERRY GENOMICS CO LTD-A BFFJRH2 5.84 7,855 45,902.56
0.85 002038 C2 BEIJING SL -A BD5CJD7 1.48 27,600 40,935.61
0.76 000078 C2 SHENZ NEPTUNUS-A BD5CBK8 0.51 71,900 36,392.22
0.71 1873 HK VIVA BIOTECH HOLDINGS BJBL0L5 0.83 41,000 34,113.20
0.52 603363 C1 FUJIAN AONONG-A BF2DZF1 2.20 11,320 24,932.54
0.52 603387 C1 GETEIN BIOTECH INC-A BFB4S90 5.08 4,900 24,876.53
0.52 6855 HK ASCENTAGE PHARMA BK9PZW2 4.51 5,500 24,793.44
0.34 6826 HK SHANGHAI HAOHA-H BWZN1R1 7.13 2,300 16,396.51
0.29 002880 C2 SHENZHEN WEIGU-A BMTCVX0 7.38 1,900 14,028.96
0.26 CASH 0.85 14,542 12,432.44
Holdings are subject to change.


Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.